Advertisement

Molecular Diagnosis of Breast Cancer

  • Lise Lotte Hansen
Chapter
  • 910 Downloads

Abstract

Breast cancer is the most prevalent disease and cause of death among women in Northern Europe and the USA. The incidence rate is still increasing, and despite early diagnosis and improved treatment, the mortality is still high. Breast cancer is a very heterogeneous disease and less than 10% of the diagnosed cases are believed to be caused by an inherited factor. The information on tumor specific genomic alterations has dramatically increased during the past decade, and seen in relation to the effect on survival and treatment efficiency, these genomic changes may prove to act as prognostic and predictive factors. The introduction of methods to screen the entire genome for alterations has led to important knowledge of tumor biology, progression and targets of therapy. This chapter describes the different kinds of genomic alterations found in the tumor, the methods to assess them and examples of correlations between the changes and prognostic or predictive parameters

Keywords

Breast Cancer Genomic Alterations Prognostic Marker Predictive Marker Genome-wide Screening 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abd El-Rehim, D.M., et al. (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer, 116: 340–50.PubMedCrossRefGoogle Scholar
  2. Akli, S. and Keyomarsi, K. (2004) Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res, 6: 188–91.PubMedCrossRefGoogle Scholar
  3. Albertsen, H.M., et al. (1994) A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21. Nat.Genet., 7: 472–479.PubMedCrossRefGoogle Scholar
  4. Alsner, J., et al. (2000) Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients [In Process Citation]. Clin Cancer Res, 6: 3923–31.PubMedGoogle Scholar
  5. Altshuler, D., et al. (2005) A haplotype map of the human genome. Nature, 437: 1299–320.CrossRefGoogle Scholar
  6. Ameyaw, M.M., et al. (2002) Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet, 47: 172–5.PubMedCrossRefGoogle Scholar
  7. Arun, B. and Goss, P. (2004) The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol, 31: 22–9.PubMedCrossRefGoogle Scholar
  8. Aubele, M., et al. (2002) Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal Cell Pathol, 24: 77–87.PubMedGoogle Scholar
  9. Bell, A.C., et al. (2001) Insulators and boundaries: versatile regulatory elements in the eukaryotic. Science, 291: 447–50.PubMedCrossRefGoogle Scholar
  10. Benusiglio, P.R., et al. (2005) Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res, 7: R204–R209.PubMedCrossRefGoogle Scholar
  11. Bergh, J., et al. (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particulary in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine, 1: 1029–1034.PubMedCrossRefGoogle Scholar
  12. Blegen, H., et al. (2003) DNA amplifications and aneuploidy, high proliferative activity and impaired cell cycle control characterize breast carcinomas with poor prognosis. Anal Cell Pathol, 25: 103–14.PubMedGoogle Scholar
  13. Borg, A., et al. (1992) Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. Genes Chromosomes Cancer, 5: 311–20.PubMedCrossRefGoogle Scholar
  14. Borresen, A.L., et al. (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes.Cancer, 14: 71–75.PubMedCrossRefGoogle Scholar
  15. Brenton, J.D., et al. (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol, 23: 7350–60.PubMedCrossRefGoogle Scholar
  16. Buerger, H., et al. (1999) Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol, 189: 521–6.PubMedCrossRefGoogle Scholar
  17. Buerger, H., et al. (2001) Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol, 194: 165–70.PubMedCrossRefGoogle Scholar
  18. Busmanis, I., et al. (1994) Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology, 26: 261–7.PubMedCrossRefGoogle Scholar
  19. Callahan, R., et al. (1993) Genetic and molecular heterogeneity of breast cancer cells. Clin Chim Acta, 217: 63–73.PubMedCrossRefGoogle Scholar
  20. Cameron, E.E., et al. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet, 21: 103–7.PubMedCrossRefGoogle Scholar
  21. Cargill, M., et al. (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet, 22: 231–8.PubMedCrossRefGoogle Scholar
  22. Ching, T.T., et al. (2005) Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet, 37: 645–51.PubMedCrossRefGoogle Scholar
  23. Cotton, R.G.H., et al. (1988) Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl. Acad. Sci. USA, 85: 4397–4401.PubMedCrossRefGoogle Scholar
  24. Cross, S.H., et al. (1994) Purification of CpG islands using a methylated DNA binding column. Nat Genet, 6: 236–44.PubMedCrossRefGoogle Scholar
  25. Dagan, E., et al. (2002) Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet, 10: 724–8.PubMedCrossRefGoogle Scholar
  26. Dandachi, N., et al. (2004) Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer. Anticancer Res, 24: 2401–6.PubMedGoogle Scholar
  27. de Jong, M.M., et al. (2005) No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors. Eur J Cancer, 41: 1819–23.PubMedCrossRefGoogle Scholar
  28. De Placido, S., et al. (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res, 9: 1039–46.PubMedGoogle Scholar
  29. Devilee, P. and Cornelisse, C.J. (1994) Somatic genetic changes in human breast cancer. Biochim.Biophys.Acta, 1198: 113–130.PubMedGoogle Scholar
  30. Dobrovic, A. (2005) Methods for analysis of DNA methylation. In: Molecular Diagnostics: For the clinical Laboratorian, Sec ed. (Eds.: Coleman, W.B. and Tsongalis, G.J.) Pages 149–160, Humana Press Inc., Totowa, NJ.Google Scholar
  31. Dressler, L.G., et al. (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol, 23: 4287–97.PubMedCrossRefGoogle Scholar
  32. Dumitrescu, R.G. and Cotarla, I. (2005) Understanding breast cancer risk – where do we stand in 2005? J Cell Mol Med, 9: 208–21.PubMedCrossRefGoogle Scholar
  33. Durbecq, V., et al. (2004) Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther, 3: 1207–14.PubMedGoogle Scholar
  34. Eifel, P., et al. (2001) National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst, 93: 979–89.PubMedCrossRefGoogle Scholar
  35. Eiriksdottir, G., et al. (1998) Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. Eur J Cancer, 34: 2076–81.PubMedCrossRefGoogle Scholar
  36. Emens, L.A. (2005) Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther, 12: 243–53.PubMedGoogle Scholar
  37. Esteller, M. (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 21: 5427–40.PubMedCrossRefGoogle Scholar
  38. Fearon, E.R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell, 61: 759–67.PubMedCrossRefGoogle Scholar
  39. Fodde, R. and Smits, R. (2001) Disease model: familial adenomatous polyposis. Trends Mol Med, 7: 369–73.PubMedCrossRefGoogle Scholar
  40. Forozan, F., et al. (2000) Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res, 60: 4519–25.PubMedGoogle Scholar
  41. Fusun, T., et al. (2005) Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients. Exp Oncol, 27: 145–9.PubMedGoogle Scholar
  42. Gaki, V., et al. (2000) Allelic loss in chromosomal region 1q21-23 in breast cancer is associated with peritumoral angiolymphatic invasion and extensive intraductal component. Eur J Surg Oncol, 26: 455–60.PubMedCrossRefGoogle Scholar
  43. Garcia, J.M., et al. (1999) Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat, 57: 237–43.PubMedCrossRefGoogle Scholar
  44. Gasparini, G., et al. (2005) Therapy of breast cancer with molecular targeting agents. Ann Oncol, 16 Suppl 4: iv28–iv36.Google Scholar
  45. Gentile, M., et al. (1999) Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: association with poor survival. Br J Cancer, 80: 843–9.PubMedCrossRefGoogle Scholar
  46. Gitan, R.S., et al. (2002) Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res, 12: 158–64.PubMedCrossRefGoogle Scholar
  47. Goldhirsch, A., et al. (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol, 21: 3357–65.PubMedCrossRefGoogle Scholar
  48. Gong, Y., et al. (2005) Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer, 103: 1763–9.PubMedCrossRefGoogle Scholar
  49. Haga, S., et al. (2001) Association of allelic losses at 3p25.1, 13q12, or 17p13.3 with poor prognosis in breast cancers with lymph node metastasis. Jpn J Cancer Res, 92: 1199–206.PubMedGoogle Scholar
  50. Han, W., et al. (2005) A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res, 11: 4775–8.PubMedCrossRefGoogle Scholar
  51. Hansen, L.L., et al. (1996) Sensitive and fast mutation detection by solid-phase chemical cleavage. Human Mutation, 7: 256–263.PubMedCrossRefGoogle Scholar
  52. Hansen, L.L., et al. (1998) Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res, 58: 2166–9.PubMedGoogle Scholar
  53. Hansen, L.L. and Justesen, J. (2003) Loss of heterozygosity, a multiplex PCR method to define narrow deleted chropmosomal regions of a tumor genome. In: PCR Primer. A laboratory manual. (Eds.: Dieffenbach, C.W. and Dveksler, G.S.) Pages 223–236, Cold Spring Harbor Laboratory Press, New York, USA.Google Scholar
  54. Harbeck, N., et al. (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer, 5: 348–52.PubMedGoogle Scholar
  55. Heikkinen, K., et al. (2005) Mutation analysis of the ATR gene in breast and ovarian cancer families. Breast Cancer Res, 7: R495–R501.PubMedCrossRefGoogle Scholar
  56. Hermsen, M.A., et al. (1998) Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J Pathol, 186: 356–62.PubMedCrossRefGoogle Scholar
  57. Hicks, D.G. and Tubbs, R.R. (2005) Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol, 36: 250–61.PubMedCrossRefGoogle Scholar
  58. Hoque, M.O., et al. (2004) Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res, 64: 5511–7.PubMedCrossRefGoogle Scholar
  59. Hoyal, C.R., et al. (2005) Genetic polymorphisms in DPF3 associated with risk of breast cancer and lymph node metastases. J Carcinog, 4: 13.PubMedCrossRefGoogle Scholar
  60. Hsiao, W.C., et al. (2004) Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study. Breast Cancer Res, 6: R180–6.PubMedCrossRefGoogle Scholar
  61. Huang, T.H., et al. (1999) Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet, 8: 459–70.PubMedCrossRefGoogle Scholar
  62. Huiping, C., et al. (1998) High frequency of LOH at chromosome 18q in human breast cancer: association with high S-phase fraction and low progesterone receptor content. Anticancer-Res, 18: 1031–6 issn: 0250-7005.PubMedGoogle Scholar
  63. Hunt, K.K. and Keyomarsi, K. (2005) Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol, 15: 319–26.PubMedCrossRefGoogle Scholar
  64. Hyman, E., et al. (2002) Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res, 62: 6240–5.PubMedGoogle Scholar
  65. Ichikawa, D., et al. (2004) Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res, 24: 2477–81.PubMedGoogle Scholar
  66. Ishkanian, A.S., et al. (2004) A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet, 36: 299–303.PubMedCrossRefGoogle Scholar
  67. Jatoi, I. and Miller, A.B. (2003) Why is breast-cancer mortality declining? Lancet Oncol, 4: 251–254.PubMedCrossRefGoogle Scholar
  68. Janssen, E.A., et al. (2003) In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol, 201: 555–61.PubMedCrossRefGoogle Scholar
  69. Judson, R. and Stephens, J.C. (2001) Notes from the SNP vs. haplotype front. Pharmacogenomics, 2: 7–10.PubMedCrossRefGoogle Scholar
  70. Kallioniemi, A., et al. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 258: 818–21.PubMedCrossRefGoogle Scholar
  71. Kammerer, S., et al. (2004) Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res, 64: 8906–10.PubMedCrossRefGoogle Scholar
  72. Keyomarsi, K., et al. (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med, 347: 1566–75.PubMedCrossRefGoogle Scholar
  73. Kinzler, K.W. and Vogelstein, B. (1996) Life (and death) in a malignant tumour. Nature, 379: 19–20.PubMedCrossRefGoogle Scholar
  74. Knudson, A. (2001) Alfred Knudson and his two-hit hypothesis. (Interview by Ezzie Hutchinson). Lancet Oncol, 2: 642–5.PubMedCrossRefGoogle Scholar
  75. Kruglyak, L. and Nickerson, D.A. (2001) Variation is the spice of life. Nat Genet, 27: 234–6.PubMedCrossRefGoogle Scholar
  76. Leitzel, K., et al. (1995) Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol, 13: 1129–35.PubMedGoogle Scholar
  77. Lo, Y.L., et al. (2005) Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int J Cancer, 115: 276–83.PubMedCrossRefGoogle Scholar
  78. Manders, P., et al. (2004) Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer, 101: 486–94.PubMedCrossRefGoogle Scholar
  79. Margolis, K.L., et al. (2005) Physical activity in different periods of life and the risk of breast cancer: the Norwegian-Swedish Women’s Lifestyle and Health cohort study. Cancer Epidemiol Biomarkers Prev, 14: 27–32.PubMedGoogle Scholar
  80. Matsumoto, S., et al. (2000) Loss of heterozygosity at 3p24-p25 as a prognostic factor in breast cancer. Cancer Lett, 152: 63–9.PubMedCrossRefGoogle Scholar
  81. Miller, B.J., et al. (2003) Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet, 73: 748–67.PubMedCrossRefGoogle Scholar
  82. Miyamoto, K., et al. (2005) Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer, 116: 407–14.PubMedCrossRefGoogle Scholar
  83. Nagahata, T., et al. (2002) Correlation of allelic losses and clinicopathological factors in 504 primary breast cancers. Breast Cancer, 9: 208–15.PubMedCrossRefGoogle Scholar
  84. Nagai, M.A., et al. (1994) Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients. Br J Cancer, 69: 754–8.PubMedGoogle Scholar
  85. Nelson, M.R., et al. (2004) Large-scale validation of single nucleotide polymorphisms in gene regions. Genome Res, 14: 1664–8.PubMedCrossRefGoogle Scholar
  86. Nexo, B.A., et al. (2003) A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55. Carcinogenesis, 24: 899–904.PubMedCrossRefGoogle Scholar
  87. Palmisano, W.A., et al. (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res, 60: 5954–8.PubMedGoogle Scholar
  88. Parkin, D.M., et al. (1999) Global cancer statistics. CA Cancer J Clin, 49: 33–64, 1.PubMedGoogle Scholar
  89. Pegram, M.D., et al. (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15: 537–47.PubMedCrossRefGoogle Scholar
  90. Pharoah, P.D., et al. (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet, 31: 33–6.PubMedCrossRefGoogle Scholar
  91. Pinto, A.E., et al. (2005) Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology, 37: 45–50.PubMedCrossRefGoogle Scholar
  92. Press, M.F., et al. (1993) Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res., 53: 4960–4970.PubMedGoogle Scholar
  93. Press, M.F., et al. (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res, 54: 2771–7.PubMedGoogle Scholar
  94. Press, M.F., et al. (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol, 20: 3095–105.PubMedGoogle Scholar
  95. Quon, K.C. and Berns, A. (2001) Haplo-insufficiency? Let me count the ways. Genes Dev, 15: 2917–21.PubMedCrossRefGoogle Scholar
  96. Ragnarsson, G., et al. (1999) Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer, 79: 1468–74.PubMedCrossRefGoogle Scholar
  97. Rebbeck, T.R., et al. (1999) Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet, 64: 1371–7.PubMedCrossRefGoogle Scholar
  98. Regitnig, P., et al. (2002) Microsatellite analysis of breast carcinoma and corresponding local recurrences. J Pathol, 198: 190–7.PubMedCrossRefGoogle Scholar
  99. Reich, D.E., et al. (2003) Quality and completeness of SNP databases. Nat Genet, 33: 457–8.PubMedCrossRefGoogle Scholar
  100. Richard, F., et al. (2000) Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer, 89: 305–10.PubMedCrossRefGoogle Scholar
  101. Ross, J.S. and Fletcher, J.A. (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells, 16: 413–28.PubMedCrossRefGoogle Scholar
  102. Ross, J.S., et al. (2004) Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics, 3: 379–98.PubMedCrossRefGoogle Scholar
  103. Rueckert, S., et al. (2005) A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab. Expert Opin Biol Ther, 5: 853–66.PubMedCrossRefGoogle Scholar
  104. Seitz, S., et al. (1997) Deletion mapping and linkage analysis provide strong indication for the involvement of the human chromosome region 8p12-p22 in breast carcinogenesis. Br J Cancer, 76: 983–91.PubMedGoogle Scholar
  105. Shi, H., et al. (2003) Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J Cell Biochem, 88: 138–43.PubMedCrossRefGoogle Scholar
  106. Shi, H., et al. (2003) Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res, 63: 2164–71.PubMedGoogle Scholar
  107. Skotheim, R.I., et al. (2001) Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet, 127: 64–70.PubMedCrossRefGoogle Scholar
  108. Smith, M.L. and Seo, Y.R. (2000) Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. Anticancer Res, 20: 2537–9.PubMedGoogle Scholar
  109. Smylie, K.J., et al. (2004) Analysis of sequence variations in several human genes using phosphoramidite bond DNA fragmentation and chip-based MALDI-TOF. Genome Res, 14: 134–41.PubMedCrossRefGoogle Scholar
  110. Sorlie, T., et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98: 10869–74.PubMedCrossRefGoogle Scholar
  111. Sorlie, T., et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100: 8418–23.PubMedCrossRefGoogle Scholar
  112. Suter, N.M., et al. (2003) Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev, 12: 127–35.PubMedGoogle Scholar
  113. Tomlinson, I.P., et al. (2002) Loss of heterozygosity analysis: practically and conceptually flawed? Genes Chromosomes Cancer, 34: 349–53.PubMedCrossRefGoogle Scholar
  114. Topaloglu, O., et al. (2004) Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res, 10: 2284–8.PubMedCrossRefGoogle Scholar
  115. Tower, G.B., et al. (2003) The 2G single nucleotide polymorphism (SNP) in the MMP-1 promoter contributes to high levels of MMP-1 transcription in MCF-7/ADR breast cancer cells. Breast Cancer Res Treat, 82: 75–82.PubMedCrossRefGoogle Scholar
  116. Tsumagari, K., et al. (2005) Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes. Breast Cancer, 12: 166–77.PubMedCrossRefGoogle Scholar
  117. Tsuneizumi, M., et al. (2002) Association of allelic loss at 8p22 with poor prognosis among breast cancer cases treated with high-dose adjuvant chemotherapy. Cancer Lett, 180: 75–82.PubMedCrossRefGoogle Scholar
  118. Utada, Y., et al. (2000) Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas. Cancer, 88: 1410–6.PubMedCrossRefGoogle Scholar
  119. van’t Veer, L.J., et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415: 530–6.CrossRefGoogle Scholar
  120. van de Vijver, M.J., et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med, 347: 1999–2009.PubMedCrossRefGoogle Scholar
  121. Waard, F.D. and Thijssen, J.H. (2005) Hormonal aspects in the causation of human breast cancer: Epidemiological hypotheses reviewed, with special reference to nutritional status and first pregnancy. J Steroid Biochem Mol Biol,Google Scholar
  122. Wang, Y., et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 365: 671–9.PubMedGoogle Scholar
  123. Weber, B.L. and Nathanson, K.L. (2000) Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer, 36: 1193–9.PubMedCrossRefGoogle Scholar
  124. Winqvist, R., et al. (1995) Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res, 55: 2660–4.PubMedGoogle Scholar
  125. Worm, J., et al. (2001) In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem, 47: 1183–9.PubMedGoogle Scholar
  126. Yan, P.S., et al. (2002) Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J Nutr, 132: 2430S–2434S.PubMedGoogle Scholar
  127. Yu, H., et al. (2000) Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat, 59: 153–61.PubMedCrossRefGoogle Scholar
  128. Zhu, Y., et al. (2004) An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res, 64: 2251–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Lise Lotte Hansen
    • 1
  1. 1.Institute of Human GeneticsThe Bartholin BuildingUniversity of AarhusDenmark

Personalised recommendations